Last Updated on October 2, 2024 by The Health Master
Days after Sun Pharma’s Halol plant was listed on an import alert by the US Food and Drug Administration (USFDA), the company said it has received a warning letter from the regulator summarizing violations at the manufacturing plant in Gujarat.
“We now wish to inform you that the company has received a warning letter from the USFDA for the Halol facility.”
“The Warning Letter summarizes violations with respect to current good manufacturing practice (cGMP) regulations.”
“USFDA shall make public the contents of the warning letter in due course,” the pharma company said in an exchange filing.
The USFDA issued an import alert last week for the Halol facility in Gujarat, and products manufactured at the facility are now subject to refusal of admission into the US market.
The decision from the USFDA came after an inspection of the facility by the USFDA from April 26 to May 9, 2022.
The Import Alert implies, inter alia, that all future shipments of products manufactured at this facility are subject to refusal of admission to the US market until the facility becomes compliant with cGMP standards, Sun Pharma said in a statement last week.
Sun Pharma has said that the supplies to the US market from the Halol facility accounted for approximately three percent of the firm’s consolidated revenues.
“The company continues to cooperate with the USFDA and will undertake all necessary steps to resolve these issues and ensure that the regulator is completely satisfied with the company’s remedial action,” it added.
The USFDA has excluded 14 products from this import alert subject to certain conditions.
USFDA issues warning letter to Glenmark’s Goa facility
USFDA issues warning letter to Lupin
USFDA issues warning letter to Lupin API plant
USFDA issues warning letter to Aurobindo Pharma for manufacturing lapses at API plant
USFDA gives warning letter to Aurobindo Pharma for API facility
Lupin gets warning letter from USFDA for Somerset facility
IPC flags drug safety alert against Minoxidil
USFDA issues Form 483 with 8 observations to Jubilant
NPPA releases 5th list of draft ceiling prices for 69 formulations
DCOIWA to conduct workshops on Drugs & Medical Devices
US Court dismisses cancer linkage associated with Ranitidine
USFDA approves this lung cancer drug
International drug racket busted in Hyderabad, two held
Drug alert: 83 out of 1487 samples declared as NSQ in November 20222
FDA: Patients cannot be forced to buy medicines from hospital-attached pharmacies
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
